Definium Therapeutics, Inc.
DFTX
$42.63
-$1.27-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -208.94% | -206.01% | -69.12% | -71.88% | -12.23% |
| Total Depreciation and Amortization | -- | -- | -- | -201.93% | -203.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -41.51% | -69.02% |
| Total Other Non-Cash Items | 2,501.48% | 920.28% | 32.22% | 40.42% | -81.36% |
| Change in Net Operating Assets | 142.41% | 438.26% | 382.21% | 295.21% | 170.75% |
| Cash from Operations | -65.37% | -57.45% | -66.26% | -53.26% | -37.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.07% | 132.53% | -- | -- | -- |
| Cash from Investing | -11.07% | 132.53% | -- | -- | -- |
| Total Debt Issued | -100.00% | 320.00% | 320.00% | 320.00% | 68.00% |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 1,245.49% | 223.56% | 1.42% | -97.79% | -57.19% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -906.03% | -108.32% | 1.94% | 96.87% | 47.51% |
| Cash from Financing | 981.08% | 219.69% | 5.56% | -90.00% | -53.10% |
| Foreign Exchange rate Adjustments | -700.00% | 138.10% | 76.67% | 87.50% | 123.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 396.50% | 206.01% | -109.14% | -255.04% | -266.15% |